Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study-Reference-Cited by-同舟云学术

Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study

Published:2007-10 Issue:4 Volume:52 Page:1020-1027
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Di Lorenzo Giuseppe,Autorino Riccardo,Perdonà Sisto,De Laurentiis Michele,D'Armiento Massimo,Cancello Giuseppe,Mirone Vincenzo,Imbimbo Ciro,Longo Nicola,Altieri Vincenzo,Tortora Gianpaolo,Figg William D.,De Placido Sabino

Publisher

Elsevier BV

Subject

Urology

Reference34 articles.

1. Cancer statistics, 2006;Jamal;CA Cancer J Clin,2006

2. Advances in prostate cancer chemotherapy: a new era begins;Pienta;CA Cancer J Clin,2005

3. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer;Yagoda;Cancer,1993

4. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

5. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nuclear Targeting Study of HPMA Copolymer-5-Fluorouracil Conjugate Based on the Subcellular Distribution in PC-3 Cells;Acta Poloniae Pharmaceutica - Drug Research;2019-04-30

2. RNF7 knockdown inhibits prostate cancer tumorigenesis by inactivation of ERK1/2 pathway;Scientific Reports;2017-03-02

3. High-Dose Calcitriol, Docetaxel and Zoledronic Acid in Patients with Castration-Resistant Prostate Cancer: A Phase II Study;Urologia Internationalis;2013

4. 7-epi-nemorosone from Clusia rosea induces apoptosis, androgen receptor down-regulation and dysregulation of PSA levels in LNCaP prostate carcinoma cells;Phytomedicine;2012-11

5. Patient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastases;Supportive Care in Cancer;2012-02-03